| Abstract: | Objective To investigate the clinical effects of Xuesaitong combined with percutaneous coronary intervention (PCI) in treatment of acute ST-segment elevation myocardial infarction (STEMI). Methods 120 patients with acute STEMI admitted into our hospital from October 2016 to October 2017 were randomly divided into two groups, 60 cases in each group. Control group was given PCI, while observation group was treated with Xuesaitong based on control group. The preoperative and postoperative 1d serum markers levels, postoperative 1d TIMI flow grades, postoperative 1d myocardial blush grade, postoperative 7d inflammatory factors levels, postoperative one-month cardiac function and adverse reactions were compared between the two groups. Results After treatment, the levels of CKMB, cTnT, hs-CRP, PTX-3, BNP, LVEDD in two groups decreased, and observation group was lower than control group (P<0.05); After treatment, the TIMI flow grades, myocardial blush grade and LVEF levels in two groups increased, and observation group was higher than control group (P<0.05); There was no statistical difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Xuesaitong combined with PCI in treatment of acute STEMI is effective, it can improve myocardial blood flow, reduce inflammatory response, improve cardiac function, have higher safety and no obvious adverse reactions, which is worthy of clinical application. |
